Strategic Governing Group - Translational Safety

Member Login


2014.08.14 John Doe

Key decision-makers in Translational Safety (TS) R&D from 16 pharma companies and representative from Innovative Medicines Initiative Joint Undertaking (IMI-JU) convened for the first time in Paris on July 7th, to launch the Strategic Governing Group Translational Safety (SGGTS).

The group’s focus is to bring together both pre-clinical and clinical expertise for the identification of predictors of safety, and the development of point-of-care assays for biomarkers and of new human biology platforms to better predict toxicity and safety during drug development.

In this first meeting, the SGGTS successfully developed a first consensus on the safety challenges developing strategic themes. These will now be addressed in game-changing, collaborative TS projects to be initiated at the end of 2014. In the upcoming meetings, the SGGTS will provide the strategic guidance for these projects and will initiate a portfolio of further projects aiming to maximize the success of this program.